Aenova Holding GmbH, a leading contract development and manufacturing organisation (CDMO), is headquartered in Germany and operates extensively across Europe and North America. Founded in 2011, Aenova has rapidly established itself in the pharmaceutical and healthcare sectors, specialising in the production of solid, semi-solid, and liquid dosage forms. The company offers a diverse range of services, including formulation development, manufacturing, and packaging, catering to both prescription and over-the-counter products. Aenova's commitment to quality and innovation has positioned it as a trusted partner for numerous global pharmaceutical companies. With a focus on sustainability and advanced technologies, Aenova continues to achieve significant milestones, reinforcing its status as a key player in the CDMO landscape.
How does Aenova Holding GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Aenova Holding GmbH's score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aenova Holding GmbH, headquartered in Germany, has set ambitious climate commitments aimed at significantly reducing its carbon emissions. Although specific emissions data for the most recent year is not available, the company has outlined clear reduction targets. By 2030, Aenova aims to achieve an 80% reduction in Scope 1 and Scope 2 emissions compared to its 2024 baseline. Furthermore, the company has committed to reaching net zero for Scope 3 emissions by 2045, targeting an overall reduction of 90%. These commitments reflect Aenova's long-term sustainability strategy, which is designed to address all scopes of emissions. The company's proactive approach to climate action is indicative of its dedication to environmental responsibility within the pharmaceutical manufacturing sector. As a current subsidiary of a larger corporate family, Aenova's initiatives align with broader industry standards and expectations for climate action.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aenova Holding GmbH has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
